Dermatomyositis antibodies continue to mys
            <scp>TIF</scp>
            y

Fiorentino, David

doi:10.1111/bjd.17497

Cited by 1 publication

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is well known that there are many methodologies currently employed to detect autoantibodies. The gold standard assay is IP using native protein as the antigen, as it is clear that the immune system overwhelmingly sees antigen in its native conformation, but this is highly labor intensive and may be influenced by protein-protein interactions and post-translational modifications of the target antigen (Table 2) (144). It should be noted that this doesn't mean IP is always "correct", just that studies should always be comparing data from their platform with that from IP, and preferentially with some phenotypic characterization of the groups to delineate how different platforms might be detecting different subsets of patients.…”

Section: The Critical Importance Of Autoantibody Assay Platform In Interpreting Autoantibody Significancementioning

confidence: 99%

Dermatomyositis autoantibodies: how can we maximize utility?

Hodgkinson¹,

Wu²,

Fiorentino³

2021

Ann Transl Med

View full text Add to dashboard Cite

The past 15 years has seen significant advances in the characterization of myositis-specific autoantibodies (MSAs) and their associated phenotypes in patients with dermatomyositis (DM). As more careful studies are performed, it is clear that unique combinations of clinical and pathological phenotypes are associated with each MSA, despite the fact that there is considerable heterogeneity within antibody classes as well as overlap across the groups. Because risk for interstitial lung disease (ILD), internal malignancy, adverse disease trajectory, and, potentially response to therapy differ by DM MSA group, a deeper understanding of MSAs and validation and standardization of assays used for detection are critical for optimizing diagnosis and treatment. Like any test, the diagnostic sensitivity and specificity of assays for various MSAs is not perfect. Currently tests for MSAs are helpful at minimum for a clinician to assess relative risk or contribute to diagnosis and perhaps counsel the appropriate patient about what to expect.With international standardization and larger studies it is likely that more antibody tests will make their way into formal schemata for diagnosis and actionable risk assessment in DM. In this review, we summarize key considerations for interpreting the clinical and pathologic associations with MSA in DM and identify critical gaps in knowledge and practice that will maximize their clinical utility and utility for understanding disease pathogenesis.

show abstract

Section: The Critical Importance Of Autoantibody Assay Platform In Interpreting Autoantibody Significancementioning

confidence: 99%